Dunedin Income Growth In... Dividends - DIG

Dunedin Income Growth In... Dividends - DIG

Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Dunedin Income Growth Investment Trust Plc DIG London Ordinary Share GB0003406096 ORD 25P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  4.00 1.45% 280.00 282.00 278.00 279.00 276.00 16:35:07
more quote information »
Industry Sector
EQUITY INVESTMENT INSTRUMENTS

Dunedin Income Growth In... DIG Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
05/12/2019InterimGBX331/01/201931/01/202006/02/202007/02/202028/02/20200
26/09/2019InterimGBX331/01/201931/01/202007/11/201908/11/201929/11/20190
13/06/2019InterimGBX331/01/201931/01/202001/08/201902/08/201923/08/20190
28/03/2019FinalGBX3.4531/01/201831/01/201902/05/201903/05/201929/05/201912.45
06/12/2018InterimGBX331/01/201831/01/201931/01/201901/02/201922/02/20190
28/09/2018InterimGBX331/01/201831/01/201901/11/201802/11/201823/11/20180
02/07/2018InterimGBX331/01/201831/01/201902/08/201803/08/201824/08/20180
29/03/2018FinalGBX4.3831/01/201731/01/201803/05/201804/05/201830/05/201812.1
16/01/20181GBX2.5731/01/201731/01/201801/02/201802/02/201823/02/20180
29/09/20171GBX2.5831/01/201731/01/201802/11/201703/11/201724/11/20170
30/06/20171GBX2.5731/01/201731/01/201803/08/201704/08/201725/08/20170
31/03/2017FinalGBX3.9831/01/201631/01/201704/05/201705/05/201726/05/201711.7
23/01/2017InterimGBX2.5731/01/201631/01/201702/02/201703/02/201724/02/20170
30/09/2016InterimGBX2.5831/01/201631/01/201703/11/201604/11/201625/11/20160
01/07/2016InterimGBX2.5731/01/201631/01/201704/08/201605/08/201626/08/20160
31/03/2016FinalGBX3.6831/01/201531/01/201605/05/201606/05/201627/05/201611.4
12/01/2016InterimGBX2.5731/01/201531/01/201604/02/201605/02/201626/02/20160
06/10/2015InterimGBX2.5831/01/201531/01/201605/11/201506/11/201527/11/20150
03/07/2015InterimGBX2.5731/01/201531/01/201606/08/201507/08/201528/08/20150
30/03/2015FinalGBX3.5330/01/201430/01/201507/05/201508/05/201529/05/201511.25
14/01/2015InterimGBX2.5730/01/201430/01/201505/02/201506/02/201527/02/20150
08/10/2014InterimGBX2.5830/01/201430/01/201506/11/201407/11/201428/11/20140
04/07/2014InterimGBX2.5730/01/201430/01/201506/08/201408/08/201429/08/20140
24/03/2014FinalGBX3.3831/01/201331/01/201407/05/201409/05/201430/05/201411.1
14/01/2014InterimGBX2.5831/01/201331/01/201405/02/201407/02/201428/02/20140
08/10/2013InterimGBX2.5731/01/201331/01/201406/11/201308/11/201329/11/20130
05/07/2013InterimGBX2.5731/01/201331/01/201407/08/201309/08/201330/08/20130
25/03/2013FinalGBX3.2531/01/201231/01/201301/05/201303/05/201331/05/201310.75
15/01/2013InterimGBX2.531/01/201231/01/201306/02/201308/02/201328/02/20130
09/10/2012InterimGBX2.531/01/201231/01/201307/11/201209/11/201230/11/20120
25/07/2012InterimGBX2.531/01/201231/01/201308/08/201210/08/201231/08/20120
26/03/2012FinalGBX6.931/01/201131/01/201218/04/201220/04/201225/05/201210.65
21/09/2011InterimGBX3.7531/01/201131/01/201228/09/201130/09/201117/10/20110
28/03/2011FinalGBX6.2531/01/201031/01/201120/04/201126/04/201125/05/201110.25
22/09/2010InterimGBX3.7531/01/201031/01/201129/09/201001/10/201008/10/20100
24/03/2010FinalGBX6.531/01/200931/01/201021/04/201023/04/201021/05/201010.25
24/09/2009InterimGBX3.7531/01/200931/07/200930/09/200902/10/200930/09/20090
01/04/2009FinalGBX6.531/01/200831/01/200922/04/200924/04/200922/05/200910.25
19/09/2008InterimGBX3.7531/01/200831/07/200824/09/200826/09/200807/10/20080
27/03/2008FinalGBX6.531/01/200731/01/200823/04/200825/04/200823/05/200810
19/09/2007InterimGBX3.531/01/200731/07/200724/09/200726/09/200709/10/20070
20/03/2007FinalGBX5.931/01/200631/01/200704/04/200710/04/200708/05/20079
11/09/2006InterimGBX3.131/01/200631/07/200620/09/200622/09/200629/09/20060
16/03/2006FinalGBX5.431/01/200531/01/200605/04/200607/04/200608/05/20068.2
08/09/2005InterimGBX2.831/01/200531/07/200514/09/200516/09/200523/09/20050
14/03/2005FinalGBX5.0531/01/200431/01/200523/03/200529/03/200529/04/20057.25
09/09/2004InterimGBX2.531/01/200431/07/200415/09/200417/09/200424/09/20040
10/03/2004FinalGBX531/01/200331/01/200417/03/200419/03/200402/04/20047.25
05/09/2003InterimGBX2.2531/01/200331/07/200317/09/200319/09/200326/09/20030
06/03/2003FinalGBX4.831/01/200231/01/200302/04/200304/04/200325/04/20037
22/08/2002InterimGBX2.231/01/200231/07/200211/09/200213/09/200227/09/20020
14/03/2002FinalGBX4.631/01/200131/01/200203/04/200205/04/200226/04/20026.75
30/08/2001InterimGBX2.1531/01/200131/07/200112/09/200114/09/200128/09/20010
15/03/2001FinalGBX4.4531/01/200031/01/200128/03/200130/03/200127/04/20016.55
24/08/2000InterimGBX2.131/01/200031/07/200004/09/200008/09/200029/09/20000
15/03/2000FinalGBX4.331/01/199931/01/200027/03/200031/03/200028/04/20006.35
26/08/1999InterimGBX2.0531/01/199931/07/199906/09/199910/09/199930/09/19990
18/03/1999FinalGBX3.7331/01/199831/01/199929/03/199906/04/199929/04/19996.18
09/03/1999InterimGBX0.4531/01/199831/01/199915/03/199919/03/199901/04/19990
27/08/1998InterimGBX231/01/199831/07/199807/09/199811/09/199830/09/19980
19/03/1998FinalGBX4.0531/01/199731/01/199830/03/199803/04/199823/04/19986

Top Dividend Posts

DateSubject
19/9/2018
10:51
speedsgh: from Fund Manager's Report in the latest Factsheet to 31/7/2018... The major share price movements within the portfolio were once again due to company specific events. French employee benefit and payments business Edenred increased sharply on the back of a very positive set of interim results, demonstrating the benefit of our overseas positioning in generating diverse and attractive investment opportunities. UK listed small cap life insurer Chesnara rebounded sharply on a broker upgrade that highlighted the significant discount to net assets and the attractive and growing dividend. Not owning Glencore also proved beneficial as the miner was hit by a potential US Department of Justice investigation into its conduct in a number of emerging markets. At a sector level oil companies lagged as hydrocarbon prices fell following a strong run since the start of the year amidst some concerns over rising US output. In contrast tobacco stocks continued to perform strongly, benefiting from solid results and a stronger dollar, partially reversing some of the very significant underperformance of the past twelve months. Pharmaceutical stocks also performed well primarily led by growing investor enthusiasm for AstraZeneca and their attractive revenue profile from new products. Activity remained relatively high as we continued to shift the portfolio towards better quality, higher growth and smaller companies. As a result we introduced new holdings in life sciences company Abcam and financial services provider London Stock Exchange. Both of these are lower yielding investments but offer the prospect of double digit dividend growth for many years ahead. Abcam is a world leading franchise specialising in the manufacture and distribution of antibodies used in scientific research. It has exceptional long–term growth prospects, a strong balance sheet and the potential to significantly increase their distributions to shareholders over time. London Stock Exchange has a very strong position in the provision of exchange, clearing, index and settlement services. This provides high and resilient levels of growth that should translate into attractive levels of dividend growth to its investors. We added further to positions in a number of mid-sized companies including Hansteen which owns a high yielding portfolio of industrial real estate, Assura the provider of primary care facilities across the UK and Aveva the leading design software provider for oil and gas, power and marine industries. At the larger end of the market cap spectrum we also increased our holding further in British American Tobacco, attracted by the elevated yield and resilient growth and National Grid where strong performance in their US assets increasingly underpins the high and steadily growing dividend. We trimmed our position in Experian given a stretched valuation following a significant increase in the share price on the back of positive results. We also exited our relatively small position in Swiss pharmaceutical giant Roche given lacklustre prospects for dividend growth and reduced our holding in HSBC where the growth outlook is also subdued and the yield no longer offers such an attractive premium to that achievable elsewhere. Our approach remains unchanged and we continue to focus on improving the medium term income and capital growth potential of the portfolio while maintaining appropriate diversity and balancing the near term requirements of our relatively high yield. Benefiting from the new combined research capabilities of the firm we have an increasingly full pipeline of attractive potential investments, particularly those focused toward capital and income growth. Finding higher yielding companies that we deem of sufficient quality for long-term investment is more challenging but we continue to evaluate a number of opportunities. All of which should allow us to position the portfolio in an increasingly differentiated manner, while underpinning the dividend policy. Equity markets remain relatively buoyant although there are a number of headwinds developing, particularly around global trade and the increasingly bellicose approach of the US to the implementation of sanctions on countries such as Turkey. As such we see little reason to shift from a conservative focus on higher quality businesses. While significant movements in large benchmark weighted stocks can affect near term relative performance, given changes to the portfolio and sound corporate performance we remain confident in the total return potential for the trust.
Your Recent History
LSE
DIG
Dunedin In..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191207 01:37:50